During the past decade, Jinling Hospital conducted 25 clinical trials. In the 10-year time frame, 25 clinical trials started and 1 clinical trials were completed, i.e. on average, 4% percent of trials that started reached the finish line to date. In the past 5 years, 9 clinical trials started and 1 clinical trials were completed. i.e. 11.1% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Jinling Hospital" #1 sponsor was "Jinling Hospital, China" with 14 trials, followed by "Nanjing PLA General Hospital" with 4 trials sponsored, "Nanjing Jinling Hospital" with 2 trials sponsored, "Boehringer Ingelheim" with 1 trials sponsored and "Chia Tai Tianqing Pharmaceutical Group Co., Ltd." with 1 trials sponsored. Other sponsors include 9 different institutions and companies that sponsored additional 19 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Jinling Hospital" #1 collaborator was "National Natural Science Foundation of China" with 6 trials as a collaborator, "The Affiliated Hospital of Qingdao University" with 2 trials as a collaborator, "Chinese PLA General Hospital" with 1 trials as a collaborator, "Clinical Medical College of Yangzhou University" with 1 trials as a collaborator and "Eli Lilly and Company" with 1 trials as a collaborator. Other collaborators include 20 different institutions and companies that were collaborators in the rest 30 trials.

According to Clinical.Site data, the most researched conditions in "Jinling Hospital" are "Crohn's Disease" (2 trials), "Gastric Cancer" (2 trials), "Multiple Myeloma" (2 trials), "Trauma" (2 trials) and "Acute Lower Gastrointestinal Dysfunction" (1 trials). Many other conditions were trialed in "Jinling Hospital" in a lesser frequency.

Most popular intervention types in "Jinling Hospital" are "Drug" (19 trials), "Procedure" (9 trials), "Other" (6 trials), "Biological" (2 trials) and "Device" (1 trials). Other intervention types were less common.

The name of intervention was led by "Dexamethasone" (2 trials), "18F-Alfatide Ⅱ PET/CT" (1 trials), "Adoptive TIL-TCM transfer therapy" (1 trials), "Anlotinib" (1 trials) and "Antibiotics (ceftazidime, cefotaxime, or meropenem, with or without vancomycin)" (1 trials). Other intervention names were less common.

The vast majority of trials in "Jinling Hospital" are 33 trials for "All" genders, 2 trials for "Female" genders and 1 trials for "Male" genders.

Currently, there are 7 active trials in "Jinling Hospital". 1 are not yet recruiting, 3 are recruiting, 2 are Active, not recruiting, and 1 are Enrolling by invitation. In total, there were 6 completed trials in Jinling Hospital, undefined suspended trials, and 1 terminated clinical trials to date.

Out of the total trials that were conducted in Jinling Hospital, 5 "Phase 1" clinical trials were conducted, 4 "Phase 2" clinical trials and 5 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 9 trials, and there were also 9 trials that are defined as “Not Applicable".